Preview Mode Links will not work in preview mode


Jun 21, 2013

Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.